Harrow Health, Inc.HROWNASDAQ
LOADING
|||
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | 15.86% |
| Q2 2025 | -5.22% |
| Q1 2025 | -36.36% |
| Q4 2024 | 109.19% |
| Q3 2024 | -25.55% |
| Q2 2024 | 42.07% |
| Q1 2024 | -35.58% |
| Q4 2023 | 134.76% |
| Q3 2023 | 22.39% |
| Q2 2023 | 58.17% |
| Q1 2023 | 4.41% |
| Q4 2022 | -9.29% |
| Q3 2022 | -15.21% |
| Q2 2022 | 38.91% |
| Q1 2022 | -82.99% |
| Q4 2021 | -37.06% |
| Q3 2021 | 1191.39% |
| Q2 2021 | -19.59% |
| Q1 2021 | 0.17% |
| Q4 2020 | -11.79% |
| Q3 2020 | -10.55% |
| Q2 2020 | 85.86% |
| Q1 2020 | -4.95% |
| Q4 2019 | -4.50% |
| Q3 2019 | -45.19% |
| Q2 2019 | 100.00% |
| Q1 2019 | -6.47% |
| Q4 2018 | 85.84% |
| Q3 2018 | 223.61% |
| Q2 2018 | -17.24% |
| Q1 2018 | -2.25% |
| Q4 2017 | 41.27% |
| Q3 2017 | -37.62% |
| Q2 2017 | -36.88% |
| Q1 2017 | -73.38% |
| Q4 2016 | 3656.25% |
| Q3 2016 | -78.95% |
| Q2 2016 | 65.22% |
| Q1 2016 | 39.39% |
| Q4 2015 | -64.52% |